Cerity Partners
BVS icon

Cerity Partners’s Bioventus BVS Stock Holding History

Cerity Partners’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,131
Closed -$118K – 2494
2024
Q4 		$118K Buy
11,131
+521
+5% +$6.16K ﹤0.01% 2318
2024
Q3 		$127K Buy
+10,610
New +$91.7K ﹤0.01% 2401

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cerity Partners's BVS Position: Q1 2025 in Review

Cerity Partners sold out of Bioventus (BVS) in Q1 2025, closing a stake of 11,131 shares — an estimated $118K sold.

Cerity Partners first reported a position in BVS in Q3 2024 and held it in 2 quarters. The position peaked at $127K in Q3 2024. 144 funds tracked by Wall St. Rank hold BVS as of Q1 2025.

  • Cerity Partners reported no remaining Bioventus position as of Q1 2025 after selling out during the quarter.
  • Cerity Partners sold 11,131 Bioventus shares in Q1 2025, an estimated $118K.
  • Cerity Partners first reported a position in Bioventus in Q3 2024 and held it in 2 quarters.
  • Cerity Partners's Bioventus position peaked at $127K in Q3 2024.
  • 144 funds tracked by Wall St. Rank held Bioventus as of Q1 2025.

Based on Cerity Partners's 13F filing for Q1 2025, filed 30 Apr 2025.